

ASX Announcement

3 November 2025

Retirement of Non-Executive Director at Upcoming AGM

Sydney, Australia – 3 November 2025: OncoSil Medical Limited (ASX: OSL) (“OncoSil Medical” or “the Company”), a medical device company focused on localised treatments for patients with unresectable locally advanced pancreatic cancer (LAPC), advises that Independent Non-Executive Director Doug Cubbin has given notice that he will retire and not stand for re-election at the Company’s upcoming Annual General Meeting (AGM) to be held on Wednesday 19 November 2025.

The Company advises that Resolution 2 concerning the re-election of Mr Cubbin as a Director, has been withdrawn. The withdrawal of this resolution will not affect the business to be conducted at the AGM, and the remaining resolutions will be put to shareholders as planned.

Mr Cubbin was appointed as a Non-Executive Director of the OncoSil Medical Board of Directors on 7 August 2023, and was subsequently promoted to Chairman of the Company on 31 August 2023.

Outgoing OncoSil Medical Non-Executive Director Mr Doug Cubbin, said: *“It has been my privilege to be a member of OncoSil Medical’s Board of Directors since August 2023. I am immensely proud of the Company’s achievements over my time on the Board, which has seen both the development and commercialisation strategies for the OncoSil™ device materially progressed. The Company is now at the stage where its innovative medical technology is available at healthcare facilities located across key target regions including the US, EU and Middle East. I wish the Company well as it continues to progress its device to market, in the process giving medical professionals an effective way to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.”*

OncoSil Medical Chairman Dr Tom Duthy, said: *“I want to personally acknowledge Doug’s invaluable contribution to OncoSil Medical’s growth since joining its Board of Directors back in August 2023. Over the intervening period, he has been an integral part of a leadership team that has mapped out and delivered the development and commercialisation strategies for our innovative OncoSil™ device. From a development angle, his time on the Board saw our Company successfully undertake trials and studies that showed the device was an effective treatment for unresectable locally advanced pancreatic cancer. And from a commercialisation angle, he oversaw a host of initiatives that have resulted in the commencement of sales in key markets. The entire Board of OncoSil Medical wish Doug well in his future endeavours.”*

Ends.

Authorisation & Additional Information

This announcement was authorised by the Board of Directors of OncoSil Medical Limited.

For further information, please contact:

<p>Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043</p>	<p>Mr. Tim Luscombe & Mr. David Wood Joint Company Secretaries E: tim.luscombe@bio101.com david.wood@bio101.com T: +61 429 707 079 & +61 408 393 670</p>	<p>Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338</p>
---	---	--

About OncoSil Medical

OncoSil Medical (ASX:OSL) is a global medical device company focused on Interventional Oncology. OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OncoSil Medical has developed OncoSil™ device for the treatment of unresectable locally advanced pancreatic cancer. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs.

Pancreatic cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with 500,000 new cases detected every year¹. Since pancreatic cancer is generally diagnosed at a later stage, it has a poor prognosis for long-term survival.

OncoSil™ has received CE Marking approval, providing marketing authorisation in both the EU and the UK. OncoSil™ is designated as a breakthrough device in both Europe and the United States. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Turkey and Israel, with commercial treatments using the device already undertaken in Spain, Italy, Austria, Greece, Turkey, and Israel.

To learn more, please visit: www.oncosil.com/

1. <https://gco.iarc.fr/en>